The approval applies to anyone aged 18 and older who has a risk of being exposed to the virus. But the FDA and the Centers ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health ...

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

Chikungunya is transmitted to humans through the bite of infected female mosquitoes, particularly Aedes aegypti and Aedes ...

The FDA and CDC recommended a pause in administering Ixchiq, a chikungunya vaccine, in adults ages 60 and above after 17 serious adverse events, including two deaths.  About 80,000 Ixchiq doses have ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

Due to an ongoing investigation of serious adverse events, it is recommended that the use of Ixchiq ® (chikungunya ... for Disease Control and Prevention (CDC). According to the Agencies, as ...

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.